Francesca Caballero, Anne Martinez-Ventura, Diego Cuicapuza, Alex Fajardo-Loyola, Rosmery Gutierrez-Ajalcriña, Javier Soto-Pastrana, Percy Asmat-Marrufo, Evelyn Barco-Yaipen de Vera, Henry Meza-Fernandez, Mario Chambi-Quispe, Jimena Pino-Dueñas, Nicomedes Laura-Rivas, Alexander Briones-Alejo, Pilar Diaz-Rengifo, Carlos Peralta-Siesquen, Guillermo Salvatierra, Pablo Tsukayama, Pool Marcos-Carbajal
{"title":"2018-2023年6个拉美国家尿路致病性大肠杆菌临床分离株基因组多样性分析","authors":"Francesca Caballero, Anne Martinez-Ventura, Diego Cuicapuza, Alex Fajardo-Loyola, Rosmery Gutierrez-Ajalcriña, Javier Soto-Pastrana, Percy Asmat-Marrufo, Evelyn Barco-Yaipen de Vera, Henry Meza-Fernandez, Mario Chambi-Quispe, Jimena Pino-Dueñas, Nicomedes Laura-Rivas, Alexander Briones-Alejo, Pilar Diaz-Rengifo, Carlos Peralta-Siesquen, Guillermo Salvatierra, Pablo Tsukayama, Pool Marcos-Carbajal","doi":"10.17843/rpmesp.2025.422.14299","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Motivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.</p><p><strong>Objective.: </strong>To genetically characterize clinical isolates of uropathogenic Escherichia coli (UPEC) from hospitals in Peru and contextualize them against 127 additional UPEC genomes reported in six Latin American countries between 2018 and 2023.</p><p><strong>Materials and methods.: </strong>The genomes of 16 Peruvian UPEC isolates were sequenced, assembled and supplemented with 127 genomes available in the NCBI public database. Serotypes, sequence types (STs), antimicrobial resistance (AMR) genes, and resistance-associated mutations were identified. A phylogenetic analysis was also conducted in order to determine evolutionary relations and distribution in phylogroups.</p><p><strong>Results.: </strong>The ST131 clone was the most prevalent (42.7%), followed by ST1193 (13.3%). Phylogroup B2 was widely predominant (83.2%), with serotype O25:H4 standing out. The resistance genes blaTEM-1, blaCTX-M-15, and blaCTX-M-27 were identified with high frequency, as well as mutations in gyrA and parC associated with fluoroquinolone resistance, especially in the ST131 clone.</p><p><strong>Conclusion.: </strong>Our findings show high circulation of high-risk UPEC clones, such as ST131 and ST1193, in Latin America, along with a notable burden of genes and mutations linked to multidrug resistance, highlighting the need to strengthen regional genomic surveillance.</p><p><strong>Background: </strong>Motivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.</p>","PeriodicalId":53651,"journal":{"name":"Revista Peruana de Medicina de Experimental y Salud Publica","volume":"42 2","pages":"156-165"},"PeriodicalIF":1.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377891/pdf/","citationCount":"0","resultStr":"{\"title\":\"Genomic diversity of uropathogenic Escherichia coli in clinical isolates from six latin american countries, 2018-2023.\",\"authors\":\"Francesca Caballero, Anne Martinez-Ventura, Diego Cuicapuza, Alex Fajardo-Loyola, Rosmery Gutierrez-Ajalcriña, Javier Soto-Pastrana, Percy Asmat-Marrufo, Evelyn Barco-Yaipen de Vera, Henry Meza-Fernandez, Mario Chambi-Quispe, Jimena Pino-Dueñas, Nicomedes Laura-Rivas, Alexander Briones-Alejo, Pilar Diaz-Rengifo, Carlos Peralta-Siesquen, Guillermo Salvatierra, Pablo Tsukayama, Pool Marcos-Carbajal\",\"doi\":\"10.17843/rpmesp.2025.422.14299\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Motivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.</p><p><strong>Objective.: </strong>To genetically characterize clinical isolates of uropathogenic Escherichia coli (UPEC) from hospitals in Peru and contextualize them against 127 additional UPEC genomes reported in six Latin American countries between 2018 and 2023.</p><p><strong>Materials and methods.: </strong>The genomes of 16 Peruvian UPEC isolates were sequenced, assembled and supplemented with 127 genomes available in the NCBI public database. Serotypes, sequence types (STs), antimicrobial resistance (AMR) genes, and resistance-associated mutations were identified. A phylogenetic analysis was also conducted in order to determine evolutionary relations and distribution in phylogroups.</p><p><strong>Results.: </strong>The ST131 clone was the most prevalent (42.7%), followed by ST1193 (13.3%). Phylogroup B2 was widely predominant (83.2%), with serotype O25:H4 standing out. The resistance genes blaTEM-1, blaCTX-M-15, and blaCTX-M-27 were identified with high frequency, as well as mutations in gyrA and parC associated with fluoroquinolone resistance, especially in the ST131 clone.</p><p><strong>Conclusion.: </strong>Our findings show high circulation of high-risk UPEC clones, such as ST131 and ST1193, in Latin America, along with a notable burden of genes and mutations linked to multidrug resistance, highlighting the need to strengthen regional genomic surveillance.</p><p><strong>Background: </strong>Motivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.</p>\",\"PeriodicalId\":53651,\"journal\":{\"name\":\"Revista Peruana de Medicina de Experimental y Salud Publica\",\"volume\":\"42 2\",\"pages\":\"156-165\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377891/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Peruana de Medicina de Experimental y Salud Publica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17843/rpmesp.2025.422.14299\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Peruana de Medicina de Experimental y Salud Publica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17843/rpmesp.2025.422.14299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Genomic diversity of uropathogenic Escherichia coli in clinical isolates from six latin american countries, 2018-2023.
Background: Motivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.
Objective.: To genetically characterize clinical isolates of uropathogenic Escherichia coli (UPEC) from hospitals in Peru and contextualize them against 127 additional UPEC genomes reported in six Latin American countries between 2018 and 2023.
Materials and methods.: The genomes of 16 Peruvian UPEC isolates were sequenced, assembled and supplemented with 127 genomes available in the NCBI public database. Serotypes, sequence types (STs), antimicrobial resistance (AMR) genes, and resistance-associated mutations were identified. A phylogenetic analysis was also conducted in order to determine evolutionary relations and distribution in phylogroups.
Results.: The ST131 clone was the most prevalent (42.7%), followed by ST1193 (13.3%). Phylogroup B2 was widely predominant (83.2%), with serotype O25:H4 standing out. The resistance genes blaTEM-1, blaCTX-M-15, and blaCTX-M-27 were identified with high frequency, as well as mutations in gyrA and parC associated with fluoroquinolone resistance, especially in the ST131 clone.
Conclusion.: Our findings show high circulation of high-risk UPEC clones, such as ST131 and ST1193, in Latin America, along with a notable burden of genes and mutations linked to multidrug resistance, highlighting the need to strengthen regional genomic surveillance.
Background: Motivation for the study. To contribute to the genomic surveillance of UPEC in clinical samples from Latin America, in response to the growing public health problem represented by UTIs and their resistance to antimicrobials. Main findings. Our study revealed a high frequency of high-risk clones, such as ST131 and ST1193. Critical mutations were identified in genes associated with resistance to multiple antibiotics, including fluoroquinolones, beta-lactams, and fosfomycin. Implications. Our results highlight the urgent need to strengthen UPEC surveillance in Latin America. Tracking resistant strains and implementing measures to limit their spread is crucial and has a significant impact on the effectiveness of available treatments.
期刊介绍:
La Revista Peruana de Medicina Experimental y Salud Pública (RPMESP) es el órgano oficial de difusión científica del Instituto Nacional de Salud (INS) del Perú. Es una publicación arbitrada por pares, de periodicidad trimestral, de ámbito y difusión mundial, indizada en MEDLINE/Index Medicos, SCOPUS, EMBASE, SciELO Salud Pública y otras bases de datos internacionales. La RPMESP es distribuida en su versión impresa y electrónica, con acceso gratuito a texto completo. La RPMESP publica artículos referidos a temas del ámbito biomédico y de salud pública, resaltando aportes prácticos, que contribuyan a mejorar la situación de salud del país y de la región. Propicia el intercambio de la experiencia científica en salud entre instituciones y personas dedicadas a la investigación dentro y fuera del Perú a fin de promover el avance y la aplicación de la investigación en salud.